Abstract-Bruxism is involuntary grinding of the teeth and can occur as a complication of brain injury. If untreated, bruxism can lead to severe occlusal trauma. Herein, we present a patient with traumatic brain injury and nocturnal bruxism that was treated with botulinum toxin injection. A 21 yr old male patient with traumatic brain injury from a car accident was admitted to our inpatient rehabilitation unit. He had a history of coma for 2 wk in the intensive care unit. The initial cranial computed tomography scan indicated a superior thalamic hemorrhage. On admission to our department 3 mo postinjury, his mental status was good and he was able to walk without assistance, but he had mild ataxia. He complained about severe teeth grinding at night, which began 2 mo postinjury. Botulinum toxin-A was injected into the masseter muscles (20 U in each muscle) and temporalis muscles (15 U in each muscle) bilaterally. A decrease in bruxism was reported within 3 d. Clinical improvement persisted at assessment 4 mo posttreatment. Botulinum toxin injection can be used as an effective treatment for bruxism associated with brain injury.
INTRODUCTION
Bruxism is a form of dystonia characterized by involuntary grinding or clenching of the teeth. Bruxism can occur while awake (diurnal bruxism) or during sleep (nocturnal bruxism) [1] . The incidence of bruxism in the general population is reported to be 21 percent, and it occurs with equal frequency in males and females but is more common in the younger population [2] . In addition, bruxism can occur as a complication of brain injury. Bruxism can lead to masseter hypertrophy, headache, periodontal disease, temporomandibular joint destruction, and tooth wear [3] . The traditional treatment for bruxism includes intraoral appliances, pharmacologic agents such as benzodiazepine, and behavioral modification techniques, but no intervention is reported to be completely effective [4] . It was hypothesized that the masseter and temporal muscles could play a role in the pathogenesis of bruxism and that botulinum toxin could be used to decrease hyperactivity in these muscles. Herein, we present a patient with bruxism following traumatic brain injury who was successfully treated with botulinum toxin-A (BTX-A).
CASE REPORT: METHODS AND RESULTS
A 21 yr old male patient with traumatic brain injury from a car accident was admitted to our inpatient rehabilitation unit. He had a history of coma for 2 wk in the intensive care unit. The initial cranial computed tomography scan indicated a superior thalamic hemorrhage. On admission to our department 3 mo postinjury, his mental status was good and he was able to walk without assistance, but he had mild ataxia. He complained about severe teeth grinding during the night that began 2 mo postinjury and was observed by his relatives. Botulinum toxin was suggested to the patient to treat bruxism.
BTX-A was injected into the patient's masseter and temporalis muscles bilaterally. The dose of BTX-A injected into each masseter and temporalis muscle was 20 U and 15 U, respectively, with a dilution of 1 mL; a 1 mL insulin syringe and a 30 G needle were used with a single injection point. The injection sites were 3 cm superior to the temporomandibular joint for the temporalis muscles and 3 cm inferior to the temporomandibular joint for the masseter muscles (Figure) .
Figure.
Injection sites for massater and temporalis muscles were 3 cm superior and inferior to temporomandibular joint (TMJ).
The patient tolerated the procedure well and there was no erythema, swelling, bleeding, infection, or muscle atrophy at the injection site and no drooling. Jaw clenching and tooth grinding decreased 3 d after the treatment. Assessment at 4 wk posttreatment showed that clinical improvement persisted.
DISCUSSION
The etiology of nocturnal bruxism is not well understood and is associated with numerous causes, including genetic factors, trauma, drugs (L-3,4-dihydroxyphenylalanine, selective serotonin reuptake inhibitors, and propranolol), and neurologic and psychiatric diseases [5] . Psychosocial factors, such as stress and behavioral changes, are typically reported in association with bruxism. Various treatments have been reported for bruxism, including intraoral guards, drugs (benzodiazepines, dopamine agents, antidepressants, muscle relaxants, and beta blockers), botulinum toxin injection, dental surgery, psychosocial interventions (i.e., relaxation techniques, stress management, and behavioral modification), physical therapy (isokinetic stretching exercises and mandibular exercises), manual therapy, and electrophysical modalities (ultrasound, shortwave diathermy, low-intensity laser therapy, transcutaneous electrical stimulation, biofeedback training, and muscular awareness relaxation therapy) [6] [7] [8] ; however, there is no consensus concerning which is most effective.
Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum. There are 7 different forms of the neurotoxin, ranging from types A through G, with type A being the most commonly used for therapeutic applications. BTX-A works by blocking the release of acetylcholine at the neuromuscular junction. The toxin binds to cholinergic nerve terminals and proteolytically inactivates SNAP-25, a synaptosomal-associated protein utilized in synaptic vesicle fusion with the nerve terminal membrane. Then, a decrease in the frequency of acetylcholine released at the synaptic cleft causes temporary muscle paralysis. Weakness of targeted muscles usually lasts between 1 and 6 mo [9] .
The side effects of botulinum toxin administration are usually minor and temporary. The primary side effects are paralysis of the wrong muscle group and allergic reactions due to the chemical structure of the molecule. Most of the studies we reviewed reported no adverse effects following treatment of bruxism with BTX-A other than predictable reactions, such as transient swelling at the injection site, low-grade fever, and soreness [10] . In the presented case, no complications of any kind occurred.
Generally, in the treatment of bruxism both the masseter and temporalis muscles are assessed during clinical evaluations and injected with BTX-A bilaterally. Usually, the total dose range is 50 to 200 U with 1 mL dilution via
